Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Geburtshilfe und Frauenheilkunde · 01.09.2024 · 84 (09) · 813-836
DOI: 10.1055/a-2344-5269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.09.2024. Verfasst von Eugen Ruckhäberle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsfrauenklinik Düsseldorf, Heinrich-Heine-Universität, CIO ABCD, Düsseldorf, Germany. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Pharma GmbH.
Abstract (Originalsprache)
Endocrine-based combination therapy with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitors) is currently the first-line therapy of choice for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−), locally advanced or metastatic breast cancer (mBC). The efficacy and safety of the treatment with palbociclib, the first CDK4/6 inhibitor approved for this indication, have been confirmed in large randomized controlled clinical trials (RCTs) with strictly defined patient cohorts. Since then, many relevant questions about CDK4/6 inhibition with palbociclib for mBC have been investigated in RCTs and real-world studies. Based on this evidence, palbociclib is widely used in clinical practice since many years because of its efficacy and good tolerability. The aim of this review is to summarize findings from RCTs and RWE considering clinically relevant aspects such as safety, tolerability, quality of life and efficacy with a focus on specific questions and patient characteristics. A critical discussion and review of the overall evidence for endocrine-based therapy with the CDK4/6 inhibitor palbociclib can contribute to support therapy decisions in daily clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Universitätsfrauenklinik Düsseldorf, Heinrich-Heine-Universität, CIO ABCD, Düsseldorf, Germany.
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Brustzentrum, Universitätsmedizin Mainz, Mainz, Germany.
- Innere Klinik (Tumorforschung), Universitätsklinikum Essen, Essen, Germany.
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, LMU Klinikum, München, Germany.
- Frauenklinik und Poliklinik, Universitätsklinikum Würzburg, Würzburg, Germany.
- Ev. Krankenhaus Bethesda Mönchengladbach, Brustzentrum Niederrhein, Mönchengladbach, Germany.
ORCID-Profile: Oleg Gluz
Förderung
- Pfizer Pharma GmbH
Zitieren
APA
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park-Simon, T. W., Untch, M., & Lux, M. P. (2024). Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer. Geburtshilfe und Frauenheilkunde, 84(09), 813-836. https://doi.org/10.1055/a-2344-5269
Vancouver
Ruckhäberle E, Schmidt M, Welt A, Harbeck N, Wöckel A, Gluz O, et al. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer. Geburtshilfe und Frauenheilkunde. 2024;84(09):813-836. doi:10.1055/a-2344-5269
BibTeX
@article{Ruckhberle2024,
author = {Ruckhäberle, Eugen and Schmidt, Marcus and Welt, Anja and Harbeck, Nadia and Wöckel, Achim and Gluz, Oleg and Park-Simon, Tjoung-Won and Untch, Michael and Lux, Michael P},
title = {Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer},
journal = {Geburtshilfe und Frauenheilkunde},
year = {2024},
volume = {84},
number = {09},
pages = {813--836},
doi = {10.1055/a-2344-5269}
}
EUVIMED